Psilocin Clinical Trial

Psychedelics biotech Tryp Therapeutics (OTCQB: TRYPF) is advancing its psilocybin-based portfolio through several recent milestones. Upcoming Phase 1 For IV Psilocin First, the company received approval from the Australian Human Research Ethics Committee (HREC) for a Phase 1 study on its IV-infused...

A Phase 1 clinical trial led by the University of California San Francisco (UCSF) assessing research partner Filament Health Corp.’s (OTCQB: FLHLF) botanical psychedelic drug candidates has shown positive interim outcomes. See also: San Francisco: Psychedelics Finally Decriminalized, Here...

Lobe Sciences (OTCQB: LOBEF), the psychedelics company performing drug R&D with sub-hallucinatory doses of psychedelics has signed a research agreement with headache medicine specialist Dr. Lauren R. Natbony, founder and CMO of Integrative Headache Medicine of New York, to assess the use of the...

Psychedelic drug discovery company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) obtained FDA approval to start the first clinical trial using naturally-sourced psychedelic substances.   Filament revealed that this authorization is the first for the direct administration of psilocin,...